An advisory panel of the Food and Drug Administration (FDA), which includes members with industry connections, has advised easing regulations on six peptides. This recommendation came despite opposition from FDA scientists, who cited a lack of sufficient data.
Peptides are increasingly promoted for a variety of uses, including accelerated healing, enhanced skin appearance, and extended lifespan. However, there is minimal evidence confirming their efficacy and safety.
On Friday, the FDA advisory committee concluded a two-day meeting by recommending the compounding of two more peptides that lack proven benefits. This decision has sparked concern over the FDA’s role in safeguarding patients from untested drugs.